G1 Therapeutics, Inc.

NasdaqGS:GTHX 주식 보고서

시가총액: US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

G1 Therapeutics 관리

관리 기준 확인 2/4

G1 Therapeutics' CEO는 Jack Bailey, Jan2021 에 임명되었습니다 의 임기는 3.58 년입니다. 총 연간 보상은 $ 3.25M, 24.5% 로 구성됩니다. 24.5% 급여 및 75.5% 보너스(회사 주식 및 옵션 포함). 는 $ 1.39M 가치에 해당하는 회사 주식의 0.37% 직접 소유합니다. 1.39M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 5.9 년입니다.

주요 정보

Jack Bailey

최고 경영자

US$3.3m

총 보상

CEO 급여 비율24.5%
CEO 임기3.7yrs
CEO 소유권0.4%
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간6yrs

최근 관리 업데이트

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

CEO 보상 분석

Jack Bailey 의 보수는 G1 Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$3mUS$795k

-US$48m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$78m

Mar 31 2023n/an/a

-US$126m

Dec 31 2022US$3mUS$764k

-US$148m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$171m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$9mUS$735k

-US$148m

Sep 30 2021n/an/a

-US$134m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$95m

Dec 31 2020US$2mn/a

-US$99m

보상 대 시장: Jack 의 총 보상 ($USD 3.25M )은 US 시장( $USD 2.41M ).

보상과 수익: 회사가 수익성이 없는 동안 Jack 의 보상이 증가했습니다.

CEO

Jack Bailey (59 yo)

3.7yrs

테뉴어

US$3,250,658

보상

Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...

리더십 팀

이름위치테뉴어보상소유권
John Bailey
CEO, President & Director3.7yrsUS$3.25m0.37%
$ 1.4m
Rajesh Malik
Chief Medical Officer10.2yrsUS$1.11m0.17%
$ 625.3k
Mark Avagliano
Chief Business Officer5.2yrsUS$1.17m0.049%
$ 186.1k
John Umstead
Chief Financial Officer1.5yrs데이터 없음0.037%
$ 138.2k
Terry Murdock
Chief Operating Officer5.7yrsUS$2.75m0.040%
$ 151.2k
William Roberts
Vice President of Investor Relations & Corporate Communications3.7yrs데이터 없음데이터 없음
Monica Thomas
Chief Legal & People Officer1.3yrs데이터 없음0.013%
$ 49.0k
Evan Hicks
Vice President of Marketingno data데이터 없음데이터 없음
Andrew Perry
Chief Commercial Officer3.1yrsUS$3.39m0.027%
$ 101.8k
Jeff Macdonald
Senior Director of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음

3.7yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: GTHX 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
John Bailey
CEO, President & Director4.5yrsUS$3.25m0.37%
$ 1.4m
Seth Rudnick
Member of Clinical Advisory Boardno dataUS$456.29k데이터 없음
Glenn Muir
Independent Director9yrsUS$172.85k0.35%
$ 1.3m
Joseph Bailes
Scientific & Clinical Advisorno data데이터 없음데이터 없음
George Demetri
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Cynthia Flowers
Independent Director6.3yrsUS$162.85k0.030%
$ 113.6k
Garry Nicholson
Independent Chairman of the Board6yrsUS$195.35k0.027%
$ 102.9k
Gary Lyman
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Norman Sharpless
Director2.2yrsUS$135.35k0%
$ 0
Kwok-Kin Wong
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Donald McDonnell
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Geoffrey Shapiro
Scientific & Clinical Advisorno data데이터 없음데이터 없음

6.0yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: GTHX 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.